Breaking News

Lotte Biologics Unveils CDMO Strategy

Syracuse plant expansion will provide contract manufacturing services for Antibody Drug Conjugates and add Drug Product fill & finish facilities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

LOTTE Biologics announced that it will join the biopharma market as a contract development and manufacturing organization (CDMO).   “With a dual-track growth strategy that includes both acquisition and new construction, LOTTE plans to quickly establish itself as a key player in the CDMO market and further strengthen its business competitiveness,” said Richard Won-jik Lee CEO.   “LOTTE will strive to provide innovative therapeutics to patients in need and leap forward as a glo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters